Keywords
COVID-19, multiple myeloma, lenalidomide
Abstract
We present a case series of three multiple myeloma (MM) patients on lenalidomide for maintenance therapy who were at high risk of coronavirus disease 2019 (COVID-19) complications and mortality. However, our patients had minor symptoms after testing positive for COVID-19 although they were unvaccinated. We think that lenalidomide might have a protective effect against severe COVID-19 symptoms.
Views: 551
HTML downloads: 124
PDF downloads: 348
Published:
2022-03-09
Issue:
2022: Vol 9 No 3
(view)